Cart
sales@molnova.com
4'-Methoxypuerarin
CAS No. 92117-94-7
4'-Methoxypuerarin( —— )
Catalog No. M24969 CAS No. 92117-94-7
4'-Methoxypuerarin is a natural product isolated from Pueraria lobata.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 238 | In Stock |
|
| 5MG | 206 | In Stock |
|
| 10MG | 304 | In Stock |
|
| 25MG | 639 | In Stock |
|
| 50MG | 892 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name4'-Methoxypuerarin
-
NoteResearch use only, not for human use.
-
Brief Description4'-Methoxypuerarin is a natural product isolated from Pueraria lobata.
-
Description4'-Methoxypuerarin is a natural product isolated from Pueraria lobata.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number92117-94-7
-
Formula Weight430.4
-
Molecular FormulaC22H22O9
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESO=C1C(C2=CC=C(OC)C=C2)=COC3=C([C@H]4[C@@H]([C@H]([C@@H]([C@@H](CO)O4)O)O)O)C(O)=CC=C13
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Frovocimab
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody to Subtilisin/Kexin Protein Converting Enzyme Type 9 (PCSK9) that binds to the catalytic domain of PCSK9 and lowers low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia.Frovocimab is used in the study of hypercholesterolemia.
-
Testolone
RAD140 is an investigational selective androgen receptor modulator (SARM) for the treatment of conditions such as muscle wasting and breast cancer.
-
Citreorosein
Citreorosein is a cAMP phosphodiesterase inhibitor, it has anti-inflammatory effect, inhibits proinflammatory cytokines production through the inhibition of both MAPKs and AKT-mediated IκB kinase (IKK) phosphorylation and subsequent inhibition of transcription factor NF-κB activation.
